Genenta is a clinical-stage biotechnology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Intrinsic immunological resistance significantly reduces the effectiveness of most cancer treatments, including leading-edge technologies such as checkpoint inhibitors and CAR-T cell therapies.

Our delivery system takes advantage of a subset of tumor-associated macrophages called TEMs (Tie-2-expressing monocytes) which normally have an affinity for and travel to tumors. Our platform engineers TEMs to deliver an immunotherapeutic payload within tumors, where it can direct the natural immune responses towards malignant cells. Our leading product, Temferon™,  has progressed into Phase 1/2a clinical trials in glioblastoma and is poised to impact other hard-to-treat cancer types.